Eli Lilly and Company $LLY Stock: Brady Family Wealth LLC Boosts Stake

Key Points

• Brady Family Wealth increased its Eli Lilly stake by 92.7% in the third quarter, to 3,501 shares valued at about $4.05 million; institutional investors collectively own 82.53% of the stock.
• Lilly beat third-quarter estimates, reporting EPS of $7.48 versus $5.71 expected and revenue up 38.6% year over year to $24.4 billion. Analysts broadly remain positive, with a consensus “Moderate Buy” rating.
• Promising trial results for retatrutide and Zepbound support Lilly’s obesity-drug growth prospects, though increasing GLP-1 price competition could pressure future revenue and profits.

Brady Family Wealth LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 92.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,501 shares of the company's stock after acquiring an additional 1,684 shares during the quarter. Brady Family Wealth LLC's holdings in Eli Lilly and Company were worth $4,051,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in LLY. BlackRock Inc. grew its holdings in shares of Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. State Street Corp grew its holdings in Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company's stock valued at $43,438,262,000 after purchasing an additional 605,752 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Eli Lilly and Company in the second quarter worth approximately $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after purchasing an additional 137,364 shares during the period. Finally, Jennison Associates LLC increased its stake in Eli Lilly and Company by 7.9% in the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock worth $6,550,587,000 after buying an additional 400,538 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on LLY shares. Argus lifted their target price on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a "buy" rating in a research report on Friday, October 30th. Truist Financial reiterated a "buy" rating and set a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday, October 30th. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an "overweight" rating in a research report on Friday, October 30th. Bank of America restated a "buy" rating and issued a $1,497.00 price target on shares of Eli Lilly and Company in a report on Friday, October 30th. Finally, Leerink Partners upped their price target on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $1,404.14.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported encouraging Phase 3 results for investigational retatrutide in people with knee osteoarthritis and obesity, including substantial weight and knee-pain reductions. New data also showed benefits from combining Zepbound with Taltz in adults with psoriatic arthritis and obesity, supporting the potential of Lilly’s obesity franchise across additional conditions. Lilly ACR Convergence data
• Positive Sentiment: Recent earnings momentum remains a support: Lilly beat Q3 estimates and raised its outlook, reinforcing expectations for strong demand for its medicines. Commentary also presents LLY as a potential defensive holding amid the technology selloff, which could attract investors seeking growth outside tech. LLY as a potential safe haven
• Negative Sentiment: Investors are also watching growing price competition in the GLP-1 market. Lower realized prices could temper the revenue and profit growth investors expect from Lilly’s highly valued obesity-drug business. GLP-1 price competition

Insider Transactions at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares of the company's stock, valued at $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $17,020,770 over the last three months. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,368.85 on Friday. The company has a market capitalization of $1.29 trillion, a PE ratio of 44.43, a P/E/G ratio of 1.77 and a beta of 0.40. The company has a 50-day simple moving average of $1,211.30 and a two-hundred day simple moving average of $1,099.50. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,453.00. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same period in the prior year, the firm posted $7.02 earnings per share. The business's quarterly revenue was up 38.6% on a year-over-year basis. Research analysts expect that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 22.46%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.